193 related articles for article (PubMed ID: 30736438)
21. EGFR inhibitors as adjuvant therapy for resected non-small cell lung cancer harboring EGFR mutations.
Tang W; Li X; Xie X; Sun X; Liu J; Zhang J; Wang C; Yu J; Xie P
Lung Cancer; 2019 Oct; 136():6-14. PubMed ID: 31421260
[TBL] [Abstract][Full Text] [Related]
22. Immunohistochemical study of thyroid transcription factor-1 and HER2/neu in non-small cell lung cancer: strong thyroid transcription factor-1 expression predicts better survival.
Haque AK; Syed S; Lele SM; Freeman DH; Adegboyega PA
Appl Immunohistochem Mol Morphol; 2002 Jun; 10(2):103-9. PubMed ID: 12051626
[TBL] [Abstract][Full Text] [Related]
23. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis.
Zhang YL; Yuan JQ; Wang KF; Fu XH; Han XR; Threapleton D; Yang ZY; Mao C; Tang JL
Oncotarget; 2016 Nov; 7(48):78985-78993. PubMed ID: 27738317
[TBL] [Abstract][Full Text] [Related]
24. Clinical and testing protocols for the analysis of epidermal growth factor receptor mutations in East Asian patients with non-small cell lung cancer: a combined clinical-molecular pathological approach.
Salto-Tellez M; Tsao MS; Shih JY; Thongprasert S; Lu S; Chang GC; Au JS; Chou TY; Lee JS; Shi YK; Radzi A; Kang JH; Kim SW; Tan SY; Yang JC
J Thorac Oncol; 2011 Oct; 6(10):1663-9. PubMed ID: 21869714
[TBL] [Abstract][Full Text] [Related]
25. Novel epidermal growth factor receptor mutation-specific antibodies for non-small cell lung cancer: immunohistochemistry as a possible screening method for epidermal growth factor receptor mutations.
Kato Y; Peled N; Wynes MW; Yoshida K; Pardo M; Mascaux C; Ohira T; Tsuboi M; Matsubayashi J; Nagao T; Ikeda N; Hirsch FR
J Thorac Oncol; 2010 Oct; 5(10):1551-8. PubMed ID: 20697298
[TBL] [Abstract][Full Text] [Related]
26. Epidermal growth factor receptor mutations in non- small cell lung cancers in a multiethnic malaysian patient population.
Liam CK; Leow HR; How SH; Pang YK; Chua KT; Lim BK; Lai NL; Kuan YC; Pailoor J; Rajadurai P
Asian Pac J Cancer Prev; 2014; 15(1):321-6. PubMed ID: 24528049
[TBL] [Abstract][Full Text] [Related]
27. Significance of epidermal growth factor receptor gene mutations in squamous cell lung carcinoma.
Miyamae Y; Shimizu K; Hirato J; Araki T; Tanaka K; Ogawa H; Kakegawa S; Sugano M; Nakano T; Mitani Y; Kaira K; Takeyoshi I
Oncol Rep; 2011 Apr; 25(4):921-8. PubMed ID: 21318227
[TBL] [Abstract][Full Text] [Related]
28. Epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation testing in adults with locally advanced or metastatic non-small cell lung cancer: a systematic review and cost-effectiveness analysis.
Westwood M; Joore M; Whiting P; van Asselt T; Ramaekers B; Armstrong N; Misso K; Severens J; Kleijnen J
Health Technol Assess; 2014 May; 18(32):1-166. PubMed ID: 24827857
[TBL] [Abstract][Full Text] [Related]
29. Impact of Tumor Suppressor Gene Co-Mutations on Differential Response to EGFR TKI Therapy in EGFR L858R and Exon 19 Deletion Lung Cancer.
Hellyer JA; White MN; Gardner RM; Cunanan K; Padda SK; Das M; Ramchandran K; Neal JW; Wakelee HA
Clin Lung Cancer; 2022 May; 23(3):264-272. PubMed ID: 34838441
[TBL] [Abstract][Full Text] [Related]
30. Prognostic impact of TTF-1 expression in patients with stage IV lung adenocarcinomas.
Schilsky JB; Ni A; Ahn L; Datta S; Travis WD; Kris MG; Chaft JE; Rekhtman N; Hellmann MD
Lung Cancer; 2017 Jun; 108():205-211. PubMed ID: 28625636
[TBL] [Abstract][Full Text] [Related]
31. EGFR activating mutations and their association with response to platinum-doublet chemotherapy in Brazilian non-small cell lung cancer patients.
Honma HN; Perroud MW; Leme MS; Barbeiro AS; Saad BA; Morcillo AM; Vassallo J; Costa DB; Zambon L
Target Oncol; 2014 Dec; 9(4):389-94. PubMed ID: 24793378
[TBL] [Abstract][Full Text] [Related]
32. [Correlation of epidermal growth factor receptor mutations and HER2/3 protein expression with clinical outcome in advanced non-small cell lung cancer patients treated with gefitinib].
Han Y; Xu JM; Duan HQ; Zhang Y; Liu XQ; Zhang JS
Chin J Cancer; 2010 Jan; 29(1):69-75. PubMed ID: 20038315
[TBL] [Abstract][Full Text] [Related]
33. Impact of HER2 expression on EGFR-TKI treatment outcomes in lung tumors harboring EGFR mutations: A HER2-CS study subset analysis.
Ohashi K; Ninomiya K; Yoshioka H; Bessho A; Shibayama T; Aoe K; Ishikawa N; Kozuki T; Kawai H; Kuyama S; Miyoshi S; Fujitaka K; Obata H; Tsubata Y; Awaya Y; Inoue M; Inoue K; Horita N; Yanai H; Hotta K; Kiura K
Lung Cancer; 2020 Dec; 150():83-89. PubMed ID: 33096420
[TBL] [Abstract][Full Text] [Related]
34. An Analysis of EGFR Mutations among 1506 Cases of Non-Small Cell Lung Cancer Patients in Guangxi, China.
Wei WE; Mao NQ; Ning SF; Li JL; Liu HZ; Xie T; Zhong JH; Feng Y; Wei CH; Zhang LT
PLoS One; 2016; 11(12):e0168795. PubMed ID: 27992557
[TBL] [Abstract][Full Text] [Related]
35. Sample features associated with success rates in population-based EGFR mutation testing.
Shiau CJ; Babwah JP; da Cunha Santos G; Sykes JR; Boerner SL; Geddie WR; Leighl NB; Wei C; Kamel-Reid S; Hwang DM; Tsao MS
J Thorac Oncol; 2014 Jul; 9(7):947-956. PubMed ID: 24922009
[TBL] [Abstract][Full Text] [Related]
36. The Utility of Thyroid Transcription Factor 1 (TTF-1), Napsin A, Excision Repair Cross-Complementing 1 (ERCC1), Anaplastic Lymphoma Kinase (ALK) and the Epidermal Growth Factor Receptor (EGFR) Expression in Small Biopsy in Prognosis of Patients with Lung Adenocarcinoma - A Retrograde Single-Center Study from Croatia.
Piljić Burazer M; Mladinov S; Ćapkun V; Kuret S; Glavina Durdov M
Med Sci Monit; 2017 Jan; 23():489-497. PubMed ID: 28128193
[TBL] [Abstract][Full Text] [Related]
37. [Correlation Study on Expression of PD-1 and PD-L1 in Non-small Cell Lung Cancer and Epidermal Growth Factor Receptor Mutations].
Jiang L; Lin Z; Li N; Jiang J; Lu C; Du S; Zhang J; Wang Y; Chen J; Gong P
Zhongguo Fei Ai Za Zhi; 2021 Sep; 24(9):623-631. PubMed ID: 34455737
[TBL] [Abstract][Full Text] [Related]
38. EGFR Mutation Subtypes Influence Survival Outcomes following First-Line Gefitinib Therapy in Advanced Asian NSCLC Patients.
Sutiman N; Tan SW; Tan EH; Lim WT; Kanesvaran R; Ng QS; Jain A; Ang MK; Tan WL; Toh CK; Chowbay B
J Thorac Oncol; 2017 Mar; 12(3):529-538. PubMed ID: 27908825
[TBL] [Abstract][Full Text] [Related]
39. Value of serum tumor markers for predicting EGFR mutations and positive ALK expression in 1089 Chinese non-small-cell lung cancer patients: A retrospective analysis.
Wang S; Ma P; Ma G; Lv Z; Wu F; Guo M; Li Y; Tan Q; Song S; Zhou E; Geng W; Duan Y; Li Y; Jin Y
Eur J Cancer; 2020 Jan; 124():1-14. PubMed ID: 31707279
[TBL] [Abstract][Full Text] [Related]
40. Epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) of Yunnan in southwestern China.
Zhou Y; Yang Y; Yang C; Chen Y; Yang C; Du Y; Zhao G; Guo Y; Ye L; Huang Y
Oncotarget; 2017 Feb; 8(9):15023-15033. PubMed ID: 28107191
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
